research use only
Cat.No.S2600
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other DNA/RNA Synthesis Inhibitors | CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 EED226 BMH-21 Carmofur Triapine (3-AP) YK-4-279 Halofuginone |
|
In vitro |
DMSO
: 56 mg/mL
(200.49 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 279.31 | Formula | C12H13N3O3S |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 59729-37-2 | -- | Storage of Stock Solutions |
|
|
| Synonyms | HOE-239, Fexinidazole Winthrop | SMILES | CN1C(=CN=C1COC2=CC=C(C=C2)SC)[N+](=O)[O-] | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
DNA synthesis
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05645822 | Withdrawn | Sleeping Sickness|Trypanosomiasis African |
Institute of Tropical Medicine Belgium|Ministry of Public Health Democratic Republic of the Congo|Institut National de Recherche Biomédicale. Kinshasa République Démocratique du Congo|SANRU Asbl Soins de Santé Primaires en Milieu Rural République Démocratique du Congo|Drugs for Neglected Diseases |
2024-01-01 | -- |
| NCT05607173 | COMPLETED | Hepatic Function Abnormal |
Sanofi |
2023-01-18 | PHASE1 |
| NCT05607173 | Completed | Hepatic Function Abnormal |
Sanofi |
2023-01-18 | Phase 1 |
| NCT03974178 | COMPLETED | Trypanosomiasis, African; Sleeping Sickness; Trypanosoma Brucei Rhodesiense; Infection |
Drugs for Neglected Diseases |
2019-09-29 | PHASE2; PHASE3 |
| NCT03025789 | COMPLETED | Trypanosomiasis, African; Sleeping Sickness; Trypanosomiasis; Gambian |
Drugs for Neglected Diseases |
2016-11-10 | PHASE3 |
| NCT03587766 | COMPLETED | Chagas' Disease (Chronic) Nos |
Drugs for Neglected Diseases |
2017-11-13 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.